Maddi Hebebrand, MC, Associate Editor

Strengthening interdisciplinary relationships remains a central part of Baker’s focus.

While dietary changes can help slightly, they’re not a cure-all for most patients with AD.

Explore the top headlines of the week including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Trials often exclude high-risk patients, limiting the real-world relevance of their safety findings.

Dupilumab becomes the first targeted therapy approved for chronic spontaneous urticaria in more than a decade.

Spearheaded by John Zampella, MD, FAAD, and Mitchell Hanson, the project highlights how art can foster community and empathy in dermatology.

Having multiple therapeutic options would allow clinicians to tailor treatment and offer hope to patients who don't respond initially.

Patients undergoing plastic surgery have the highest prevalence of BDD at 24%.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Genetic proxies for PCSK9 inhibition were consistently associated with reduced vitiligo risk across 2 biobanks.

Tapinarof offers sustained relief for atopic dermatitis, enabling treatment-free periods and long-term disease control—even in young children.

Phototherapy, commonly used for vitiligo, might help reduce cardiovascular risk through anti-inflammatory effects.

In a large study, nearly half of SIND patients also had other BFRBs like skin picking or hair pulling.

Untreated or undertreated AD can lead to poor sleep, infections, and stunted development.

Experts explore how rosacea research is evolving, with new treatments, gaps in care, and a push for more inclusive, targeted approaches.

Explore the top headlines of the week including insights on infection risks, drug updates, and more.

This week, we feature top articles from our sister publications on FDA approvals, innovative tech updates, and more.

Satisfaction levels remained high at 12 weeks post-treatment among those who received acupuncture.

While approved for vitiligo and atopic dermatitis, ruxolitinib cream may help treat other inflammatory skin diseases.

Microneedles successfully penetrated simulated skin barriers, suggesting their effectiveness in reaching sebaceous glands.

Bill Damsky, MD, PhD, pioneers molecular diagnostics to close the gap between research and clinical care in inflammatory skin disease.

Physicians can customize treatment depth and intensity with Avava’s system, improving results for various skin concerns.

Treatment decisions are increasingly guided by patient values, preferences, and quality-of-life considerations.

Compared to untreated patients, dupilumab-treated women showed no increased risk for spontaneous abortion, gestational diabetes, or hypertensive disorders.

The guide prepares students to critically engage with AI tools and understand their real-world implications.

Current JAK inhibitors are approved only for those 12 and older, leaving younger patients without access.

Explore the top headlines of the week including insights on pandemic risks, weight loss medications, and more.

This week, we feature top articles from our sister publications on the future of health care, FDA approvals, and more.

The study found dupilumab-treated patients had the highest probability of remaining infection-free over 52 weeks.